Please login to the form below

Not currently logged in
Email:
Password:

COPD

This page shows the latest COPD news and features for those working in and with pharma, biotech and healthcare.

FDA hands GSK a reprieve by blocking Novartis generic

FDA hands GSK a reprieve by blocking Novartis generic

Earlier this week GSK said it was factoring in the possibility of generic challengers to the chronic obstructive pulmonary disease (COPD) and asthma blockbuster in the US this year, despite regulatory ... The delay to Novartis’generic therefore looks

Latest news

  • Gilead’s triple HIV drug approval prompts GSK lawsuit Gilead’s triple HIV drug approval prompts GSK lawsuit

    vaccine Shingrix and recently-approved triple therapy for chronic obstructive pulmonary disorder (COPD) Trelegy - as it faces the imminent threat of generic competition to its big-selling respiratory drug Advair (salmeterol

  • AZ’s COPD triple data sets up market clash with GSK AZ’s COPD triple data sets up market clash with GSK

    budesonide - showing that the product achieved significant improvements in a range of lung function tests in COPD patients compared to various two-drug combinations. ... forward to the ETHOS exacerbation trial results in 2019 that will further

  • AZ gets EMA green light for severe asthma drug Fasenra AZ gets EMA green light for severe asthma drug Fasenra

    GSK despite arriving to market well behind the leader, which has also picked up an additional approval in chronic obstructive pulmonary disease (COPD) and is in late-stage trials for other ... It also has a follow-up trial in COPD in play. Fasenra is

  • Sanofi and Regeneron ramp up immuno-oncology collaboration Sanofi and Regeneron ramp up immuno-oncology collaboration

    The injection of funds is intended to help accelerate planned new studies in chronic obstructive pulmonary disease (COPD), peanut allergy and grass allergy, as well as in patients who have multiple ... COPD. 9th January 2018.

  • After some big setbacks, Sanofi talks up its R&D portfolio After some big setbacks, Sanofi talks up its R&D portfolio

    Sanofi is highlighting half a dozen phase IIII programmes in the update, including dupilumab as a treatment for chronic obstructive pulmonary disease (COPD), oral GCS inhibitor venglustat for polycystic kidney disease,

More from news
Approximately 72 fully matching, plus 222 partially matching documents found.

Latest Intelligence

  • Significant figures Significant figures

    NTM is a rare progressive, destructive infection that’s normally found in addition to pulmonary diseases such as chronic obstructive pulmonary disease (COPD), cystic fibrosis or bronchiectasis.

  • The good, the bad and the ugly The good, the bad and the ugly

    Its revenues grew by a further 9% last year. “A large percentage of this growth was driven by Ellipta, but Nucala - a biologic approved for asthma and COPD - also played its ... The category has also seen the recent introduction of a major drug class

  • Asthma: beyond the blue and the brown Asthma: beyond the blue and the brown

    Combine asthma with other respiratory diseases, including chronic obstructive pulmonary disease (COPD), and it contributes to more than 4 million deaths every single year, a stagnated figure that has seen no ... This year, Circassia established a

  • The cultural construction of illness The cultural construction of illness

    Work we conducted on COPD (Chronic obstructive pulmonary disease) in the US demonstrated this. ... There was an assumption among many people working in the category that the nature of COPD needed to be played down.

  • The invisible army The invisible army

    Studies with COPD and chronic kidney disease patients indicate that carers can have a positive influence on patient adherence to medication and healthy behaviours, thus driving positive outcomes in the process.

More from intelligence
Approximately 0 fully matching, plus 30 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Innovating with what you have: better healthcare with existing technology

    services. Case Study: Telephony patient service improves COPD outcomes. Berkshire Healthcare NHS Foundation Trust and Heatherwood and Wexham Park Hospitals NHS Foundation Trust together identified  a need to help patients with ... severe Chronic

  • Raising Awareness: It’s World COPD Day today!

    and education events.Raising awareness of COPD is an important part of COPD day. ... Inhaled corticosteroids (ICS) are another COPD treatment used to reduce inflammation in the lungs.

  • Synergy Vision

    In light of today (18th November 2015) being World COPD Day, it’ s never too late to raise further awareness on this disease. ... Many people suffer with Chronic Obstructive Pulmonary Disease (COPD), and many others are not aware of signs meaning they

  • Our nursing heroes

    For one chronic obstructive pulmonary disease (COPD) patient in the US, it meant more time with his grandchild. ... I really believe what we do with COPD patients in their own homes as clinical educators is making a big difference to their lives.”.

  • Using mobile “diary” research to capture patient-generated insights in COPD

    Our latest case study demonstrates how a mobile app methodology was used to deliver key insights into issues faced by COPD patients. ... Using this approach, we believed our clients could better understand the issues faced by patients, which would help

More from PMHub
Approximately 1 fully matching, plus 15 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
PharmiWeb Solutions

PharmiWeb Solutions creates, delivers and manages digital solutions for the pharmaceutical and healthcare segment. From digital marketing, to patient education...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics